$4.58
MaxCyte is a medical devices business based in the US. MaxCyte shares (MXCT) are listed on the NASDAQ and all prices are listed in US Dollars. MaxCyte employs 143 staff and has a trailing 12-month revenue of around $44.1 million.
Our top picks for where to buy MaxCyte stock
How to buy MaxCyte stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – MXCT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy MaxCyte stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
MaxCyte stock price (NASDAQ: MXCT)
Use our graph to track the performance of MXCT stocks over time.MaxCyte shares at a glance
Latest market close | $4.51 |
---|---|
52-week range | $2.45 - $5.55 |
50-day moving average | $4.49 |
200-day moving average | $4.30 |
Wall St. target price | $9.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.35 |
Is it a good time to buy MaxCyte stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
MaxCyte price performance over time
Historical closes compared with the close of $4.51 from 2024-07-22
1 week (2024-07-17) | -10.16% |
---|---|
1 month (2024-06-24) | 7.64% |
3 months (2024-04-24) | 20.59% |
6 months (2024-01-24) | -10.87% |
1 year (2023-07-24) | -5.65% |
---|---|
2 years (2022-07-22) | -13.93% |
3 years (2021-07-20) | N/A |
5 years (2019-07-20) | N/A |
MaxCyte financials
Revenue TTM | $44.1 million |
---|---|
Gross profit TTM | $39.2 million |
Return on assets TTM | -10.98% |
Return on equity TTM | -15.42% |
Profit margin | -83.01% |
Book value | $2.17 |
Market Capitalization | $518.1 million |
TTM: trailing 12 months
MaxCyte share dividends
We're not expecting MaxCyte to pay a dividend over the next 12 months.
MaxCyte share price volatility
Over the last 12 months, MaxCyte's shares have ranged in value from as little as $2.45 up to $5.545. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MaxCyte's is 1.139. This would suggest that MaxCyte's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put MaxCyte's beta into context you can compare it against those of similar companies.
- Sqz Biotechnologies Co (SQZ.US): 2.707
- Onconova Therapeutics (ONTX.US): 1.349
- Cleveland BioLabs (CBLI.US): 0.6837
MaxCyte overview
MaxCyte, Inc. , a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Frequently asked questions
What percentage of MaxCyte is owned by insiders or institutions?Currently 1.452% of MaxCyte shares are held by insiders and 74.38% by institutions. How many people work for MaxCyte?
Latest data suggests 143 work at MaxCyte. When does the fiscal year end for MaxCyte?
MaxCyte's fiscal year ends in December. Where is MaxCyte based?
MaxCyte's address is: 9713 Key West Avenue, Rockville, MD, United States, 20850 What is MaxCyte's ISIN number?
MaxCyte's international securities identification number is: US57777K1060
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question